RecruitingNot ApplicableNCT06453057

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

Sponsor

Grit Biotechnology

Enrollment

18 participants

Start Date

Jul 4, 2024

Study Type

INTERVENTIONAL

Conditions

Adult

Summary

This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria8

\. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
\. Age 18 to 70 years old;
\. Ovarian cancer that progresses after recurrence or first-line chemotherapy；
\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
\. Expected survival time of ≥ 12 weeks;
\. Good function of vital organs;
\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;
\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.

Exclusion Criteria5

Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;
Known mental illness, alcoholism, drug use or substance abuse;
Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;
Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;
The investigators determine that other conditions that make the patient not suitable for enrollment.

Interested in this trial?

Get notified about updates and connect with the research team.